Literature DB >> 23147154

Differential in vitro activity of the DNA topoisomerase inhibitor idarubicin against Trypanosoma rangeli and Trypanosoma cruzi.

Momodou Jobe1, Charles Anwuzia-Iwegbu, Ama Banful, Emma Bosier, Mubeen Iqbal, Kelly Jones, Suzanne J Lecutier, Kasimir Lepper, Matt Redmond, Andrew Ross-Parker, Emily Ward, Paul Wernham, Eleanor M Whidden, Kevin M Tyler, Dietmar Steverding.   

Abstract

In this study the effect of eight DNA topoisomerase inhibitors on the growth Trypanosoma rangeli epimastigotes in cell culture was investigated. Among the eight compounds tested, idarubicin was the only compound that displayed promising trypanocidal activity with a half-maximal growth inhibition (GI(50)) value in the sub-micromolar range. Fluorescence-activated cell sorting analysis showed a reduction in DNA content in T. rangeli epimastigotes when treated with idarubicin. In contrast to T. rangeli, against Trypanosoma cruzi epimastigotes idarubicin was much less effective exhibiting a GI(50) value in the mid-micromolar range. This result indicates that idarubicin displays differential toxic effects in T. rangeli and T. cruzi. Compared with African trypanosomes, it seems that American trypanosomes are generally less susceptible to DNA topoisomerase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23147154     DOI: 10.1590/s0074-02762012000700018

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  1 in total

1.  Online fast Biospeckle monitoring of drug action in Trypanosoma cruzi parasites by motion history image.

Authors:  Mohammad Zaheer Ansari; Hilda C Grassi; Humberto Cabrera; Ana Velásquez; Efrén D J Andrades
Journal:  Lasers Med Sci       Date:  2016-06-27       Impact factor: 3.161

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.